CANDRIAM

A NEW YORK LIFE INVESTMENTS COMPANY

Candriam Impact One

Quarterly Report

Commercial document intended exclusively for Professional Investors

September 30th, 2021

Investor letter

Dear investors,

In Q3-2021 we have been active in meeting big institutional investors thanks to the approval for the extension of our subscription period. We had promising feedbacks and are currently in due diligence process. Our diversified portfolio consists so far in 5 investment across various sectors such as HealthTech, Life Sciences, Circular Economy and Climate, starting to deploy capital.

Our underlying funds are benefiting from a number of compelling opportunities across sectors and impact themes: decent work, basic needs, resource securities, climate security, healthy ecosystem and well-being.

Yotta, focus on the development of French industry 4.0 SMEs with a 25% CO2 reduction target on the portfolio level. The fund has been quite active in Q3, finalising three investments that are described further in the reporting. Yotta is now categorized as an "Article 9" fund, which makes it one of the few French PE pioneers to be committed to the quantitative measurement of extra financial objectives, specially on decarbonisation goals.

During the period Impact Partners with its Impact Growth IV fund realized 3 investments out of which 2 are in the health tech sector. We are seeing an increasing number of opportunity on this thematic. There are 2x more HealthTech startups per capita in the EU vs the US but there only 1/9th that get growth funding as those start up goes commercial. Our Impact funds are addressing these funding gaps.

Lauxera joint expertise in operators and investors in public and private markets in EU and US combined with a broad industry mandate on the HealthTech sector is delivering good value to their portfolio companies. In each of the underlying companies they work on delivering positive impact through affordability across all investments. The success of their investment requires delivering healthcare better, faster and cheaper. During the quarter they closed their third investment. More than 80% of assessed deals were in Europe.

As of September 31th, 2021 Sofinnova industrial Biotech II committed capital is EUR 131m and recently announced its final closing. The fund completed its second investment in October 2021 in Elicit Plant a French AgriBioTech that will be further described.

Rubio has finalized fund raising and achieved their hard cap to EUR 110m. Their deal flow is strong and they completed 4 new deals described in this reporting. This bring the number of underlying invested companies to 28.

As of Q3-2021, Candriam Impact One has called 11.5% of its total commitments and received 2 capital calls over this quarter. Fundraising has continued, we are signing one subscription agreement and are actively working with two promising investors.

Candriam Impact One is now supporting 28 mission-driven companies across 6 impact themes with predominance on basic needs and wellbeing. We are seeing an increasing number of opportunity and are currently working on the due diligences of two Impact funds based in Germany.

We hope you are all safe,

Sincerely, Impact One Team







PORTFOLIO

> NEW PORTFOLIO COMPANIES



Fund details

Name	Candriam Impact One
Legal form	FPCI
Fund's domicile	France
Financial year-end of the Fund	31 December
Fund base currency	EUR
Investment Manager	Candriam France 40 rue Washington F-75408 Paris Cedex 08 France
AMF Registration #	GP03007
Commitment Amount	EUR 26 000 000
A Shares subscribed (EUR 1 000 / share)	26 000 A shares
B Shares subscribed (EUR 1 000 / share)	0 B shares
First closing:	25/05/2020
Vintage year (Date of 1st capital call):	2020
Subscription period	1 year + 6 months
Maturity	12 years
End of investment period	25 May 2024
Management Fees	0.50%
Financial Hurdle	3%
Impact Hurdle	50%



Fund indicators as at September 30th 2021

Total committed capital	EUR 26,000,000
GP commitment	0.5% of total committed capital at final closing
Contributed capital	EUR 3,000,000
History of contributions	15 June 2020EUR 500 00019 January 2021EUR 500 00026 February 2021EUR 500 0001 June 2021EUR 500 00028 July 2021EUR 500 000August 25 2021EUR 500 000
Net Assets	EUR 2,406,195
Net Assets + Callable Capital	EUR 25,406,195
Invested Amount + Callable Capital	EUR 25,550,703
Portfolio (cost of all acquisitions)	EUR 2,550,703
Portfolio (at valuation, including exits)	EUR 2,299,681
Distributed Capital	EUR 0
History of distributions to LPs	EUR 0
History of distributions to GPs	EUR 0
% of Fund invested since inception:	9.8%
% of contributed capital distributed to LPs	0.0%
Ratios	
Distributions / Contributed Capital	0.0%
Net Asset / Contributed Called	80.2%
(Distributions + Net Asset) / Contributed Capital	80.2%
Distributions / Total Committed Capital	0.0%



A shares since fund inception as at September 30th, 2021

A share inception Value	EUR 1,000.00
Contributed Capital	EUR 115.38
Distributed Capital	-
Management Fees	EUR 1.71
Other Charges	EUR 11.15
Allocation to Carried Interest	-
A share Net Asset Value	EUR 92.54
Callable Distributed Capital	EUR 0.00
Uncalled Capital	EUR 0.00



Other Financial Information

Fees and Provisions for Q3-2021

Management fees	EUR 16,419
Custodian fees	EUR 3,809
Audit fees	EUR 1,765
Transaction fees	EUR 12,003
Legal fees	EUR 0
Organisational expenses	EUR 0
Others	EUR 0



Fund Activity during Q3-2021

Capital Calls Sent

Over the quarter, two capital calls were sent to LPs for a aggregated amount of EUR 1,000,000

Capital Calls Received

Over the quarter, 7 capital calls were received from:

2x Rubio Impact Fund II Coöperatie U.A EUR 144,836
1x Sofinnova Industrial Biotech II EUR 155,000
1x Lauxera Growth I S.L.P. EUR 60,000
1x Impact Croissance IV EUR 143,000
2x Yotta Smart Industry Fund EUR 660,400



Fund Activity during Q3-2021

Commitments

No new commitment was signed on Q3-2021

Distribution

► N/A

Research

Over the course of Q3, the team has been actively working on a new transaction with a German based Impact manager which we expect to close during the next quarter or early Q1-2020













Residual portfolio valuation as of September 30th

Investment			Commitme	nt				Inves	tment Status		
Position	Country	Date	Amount (EUR)	%TCC	%Membership	% Called	Cost	Valuation	Distribution	PnL	Multiple
1 Rubio Impact Fund II Coöperatie U.A	Netherlands	11/23/2020	2,500,000	9.62%	3.04%	16.4%	410,703	364,374	-	- 46,329	0.89x
2 Impact Croissance IV	France	11/17/2020	2,600,000	10.00%	2.48%	22.6%	587,600	514,777	-	- 72,823	0.88x
3 Lauxera Growth I S.L.P.	France	1/4/2021	2,000,000	7.69%	1.20%	29.1%	582,000	554,316	-	- 27,684	0.95x
4 Sofinnova Industrial Biotech II	France	2/12/2021	3,100,000	11.92%	2.36%	10.0%	310,000	272,896	-	- 37,104	0.88x
5 Yotta Smart Industry Fund	France	6/18/2021	2,600,000	10.00%	1.97%	25.4%	660,400	593,319	-	- 67,081	0.90x
Total			12,800,000	49.2%		9.8%	2,550,703	2,299,681	-	- 251,022	

 Net Unrealised Gain (Loss) on portfolio Investments
 -EUR 251,022

 Gross Portfolio Multiple
 0.9x



Portfolio

Fund		Company	Investment	% Ownership	Multiple	Impact performance
Rubio Imp	act Fund	II				
	1	Wakuli	EUR 1,250,000	28.00%	1x	1%
	2	Mosa Meat BV	EUR 1,500,000	1.00%	1x	0%
	3	Skillab BV	EUR 1,500,000	N/A	1x	1%
	4	Incision	EUR 2,000,000	10.60%	1x	7%
	5	Litterati	EUR 493,000	N/A	1x	16%
	6	Arborea	EUR 702,000	5.60%	1x	0%
	7	Taylor	EUR 600,000	NA	1x	0%
	8	360MHz	EUR 600,000	NA	1x	0%
	9	Lingvist	EUR 2,500,000	10%	1x	0%

Fund		Company	Investment	% ownership	Multiple	Impact performance
Impact Cro	issance I	V				
	1	Mi Cuento	EUR 1,250,007	18.91%	0.9x	2%
	2	Choose my Company (CMC)	EUR 1,786,906	21.30%	1x	5%
	3	Dans ma Culotte	EUR 2,730,120	33.84%	0.76x	2%
	4	Percko	EUR 3,002,896	18.68%	1x	3%
	5	Okeenea	EUR 3,000,000	45.20%	1x	0%
	6	Neuronation	EUR 2,737,767	28.01%	1x	12%
	7	Wefight	EUR 1,615,281	9.76%	1x	0%
	8	360 Medical	EUR 2,572,421	8.14%	1x	0%
	9	Top Doctors Holding	EUR 3,735,012	8.68%	1x	0%
	10	Chromaviso Holding	EUR 2,254,870	23.48%	1x	0%
	11	Abogados	EUR 10,453,111	29.68%	1x	0%

Fund		Company	Investment	% ownership	Multiple	Impact performance
Lauxera Gr	owth I S.	L.P.				
	1	Caresyntax Corporation	EUR 8,300,000	3.00%	1x	26%
	2	Lumicks	EUR 12,600,000	5.00%	1x	5%
	3	PSIH	EUR 24,000,000	61.0%	1x	33%
Fund		Company	Investment	% ownership	Multiple	Impact performance
Sofinnova	Industria	al Biotech II				
	1	Meiognix	EUR 1,999,866	17.70%	1x	0%
Fund		Company	Investment	% Ownership	Multiple	Impact performance
Yotta						
	1	Groupe R&D / Folan	EUR 4,500,000	10.5%	1x	0%
	2	AET Technologies	EUR 6,200,000	44%	1x	0%
	3	DBC	EUR 4,500,000	44%	1x	0%
	4	RECIF	EUR 8,600,000	67%	1x	0%







PORTFOLIO







	Name Business	Chromaviso Holding Specialist in circadian lighting for healthcare (psychiatry, intensive care / rehabilitation and dementia care) in the Nordics.	The Impact problem SDG	Europe and North America spend eir day inside which goes up to 99% alised people. The lack of natural ts heath, causing sleep deprivation, epression, and delayed recovery.	
	Theme	Healthcare			
	Location	Denmark	Impact Goals	KPI 1	number of elderly in retirement homes with circadian lights
	Inception	2006			
	Exit perspective	Investment fund; Industrial buyers		KPI 2	Number of beds in hospitals and psychiatric wards equipped with circadian lights
	Date of investment	November 2021			
	Туре	Equity	% Impact Achieved		
	Amount invested	EUR 1.4 million	Achieved		
	Commitment	EUR 1.4 million			
	% ownership	23.48%			
500	Enterprise value	EUR 7.9 million			
5	Turnover	EUR 4.5 million			
	Adjusted EBITDA	EUR 0.2 million			

Company

Investment

Financial



Guadana	Name Business	Abogados Expert law firm in the law of "Segunda Opirtunidad" (Second Change Law), that offers a specialist and affordable service that helps people reduce the over indeptbness.	The Impact problem SDG	Over-debtedness is a significant phenomenon in Europe concerning 14% of EU population. Single-parents households poor households or to some extent people ages 65+ could be more affected.		
,	Theme	Underserved communities				
	Location	Barcelona ▼ 2017	Impact Goals	KPI 1	Cumulative number of clients at risk of poverty w ho had their debt reduced through the services of Abogados	
	Inception Exit perspective	Claim specialist; law firm; Tech buyer		KPI 2	Cumulative amount of debt cancelled for the customers of 1st KPI (in m EUR)	
	Date of investment	August 2021				
	Туре	Equity	% Impact Achieved			
	Amount invested	EUR 1 million	Achieved			
	Commitment	EUR 1 million				
	% ownership	29.68%				
5	Enterprise value	EUR 2.7 million				
5	Revenue	EUR 1.4 million				
•	EBITDA	EUR -0.1 million				



Company

Investment

Financial



Company	Name Business	Arborea Closed, photosynthesis based, cultivation system to grow microalgae. This system produces food ingredients, generates oxygen and sequestrates CO2, whilst can be employed on barren land.	e. Using abundant feedstock (ambient Co sunlight) and being independent of soi system addresses global resource constraints, and preserves natural environment SDG		
-	Theme	Circular Solutions			
	Location	London	Impact Goals	KPI 1	Technology Readiness Level (TRL) # achieved
	Inception	2015			()
	Exit perspective	No considerations		KPI 2	Environmental footprint in CO2 equivalent emissions/kg
	Date of investment	July 2021			
lent	Туре	Equity	% Impact		
Investment	Amount invested	EUR 0.7 million	Achieved		
lnv	Commitment	EUR 0.7 million			
	% ownership	5.6%			
	1				
cial	Enterprise value	N/A			
Financial	Revenue	N/A			
Fir	EBITDA	N/A			



taylor.

Name Business	Taylor Developed a micro-electronic technology which makes solar panels more efficient and reliable. These micro-electronics are integrated into the solar panel by the solar panel manufacturer to whom Taylor sells their product.	The Impact problem SDG	enable a h This energ the energy	uces the emissions of CO2 as they higher energy yield per solar panel. gy does not need to be supplied by grid which still heavily relies on s for energy production.
Theme	Circular Solutions			
Location	Eindhoven	Impact Goals	KPI 1	Kiloton CO emissions avoided
Inception	2017			
Exit perspective	No considerations			
Date of investment	July 2021			
Туре	Convertible Loan	% Impact		
Amount invested	EUR 0.6 million	Achieved		
Commitment	EUR 0.6 million			
% ownership	N/A			
Enterprise value	N/A			
Revenue	N/A			
EBITDA	EUR -1.0 million			



Investment

Financial



Name Business	30MHz Sells affordable plug & play climate data platform giving (controlled area) growers access to previously inaccessible high quality data to improve their farming practices. The platform offers agri-consultants to develop custom applications to enrich	The Impact problem SDG	resources	rm results in a reduction of use of , whilst simoultaneously increasing nd lowering biological loss.
	data and convert this to advice.			
Theme	Circular Solutions			
Location	Amsterdam	Impact Goals	KPI 1	Number of high tech customers
Inception	2014			
Exit perspective	No considerations.		KPI 2	Number of mid/low tech customers
Date of investment	July 2021			
Туре	Convertible Loan	% Impact		
Amount invested	EUR 0.6 million	Achieved		
Commitment	EUR 0.6 million			
% ownership	N/A			
Enterprise value	N/A			
Revenue	N/A			
EBITDA	N/A			



Investment





Company	Name Business	Lingvist A language learning app, which is customizable and offers personalized learning, and as such will in the next years be integrated with Spotify, Amazon (Kindle) and Netflix to recommend music, books and movies based on learner proficiency and interests.	The Impact problem SDG	amongst others through language learning, which will lead to significant socio-economic, cognitive and scientific advancements.		
	Theme	People Power				
	Location	Tallin (Estonia)	Impact Goals	KPI 1	Relevant language learning users	
	Inception	2014				
	Exit perspective	No consideration.				
	1					
	Date of investment	Sept 2021				
Investment	Туре	Equity, 1.0x NPLP	% Impact Achieved			
estn	Amount invested	EUR 2.5 million	Achieved			
lnv(Commitment	EUR 2.5 million				
	% ownership	10%				
	1					
cial	Enterprise value	N/A				
Financial	Revenue	N/A				
Fir	EBITDA	N/A				





	Name Business	Groupe PSIH Provides market-leading IT solutions for hospitals and healthcare- focused organizations, with a product offer articulated around two core verticals: Value-added software and healthcare data services and Healthcare data hosting services.	The Impact problem SDG	Supporting public hospitals in steering their core activities, reducing their costs and improving their control functions.
)	Theme Location Inception Exit perspective	Healthcare data managmenet Lyon 7 1998 Trade sale to a strategic actor	Impact Goals	KPI1 Time saved/month/active user
	Date of investment Type Amount invested Commitment % ownership	August 2021 Growth Buy-Out EUR 24 million EUR 24 million 61%	% Impact Achieved	
	Enterprise Value Revenue Gross profit	EUR 68 million EUR 11.8 million EUR 111.3 million		



Investment





Name Business	AET Group AET and PyroxTMdesign ,manufacture and market a wide range of customized and standard industrial furnaces. Aloxtec, designs and manufactures state-of-the-art wet thermal oxidation furnaces for VCSEL.	The Impact problem SDG	mostly de furnace us	o carbon footprint is pendent on the clients' sage (Score3 am, 66% of the carbon
Theme Location Inception Exit perspective	Industrial electric furnaces production Meylan 7 1968 N/A	Impact Goals	KPI 1	Reduce carbon emissions by 25%
Date of investment Type Amount invested Commitment % ownership	July 2021 Buy-in, majority stake EUR 6.2 million EUR 6.2 million 44.3%	% Impact Achieved		
Enterprise Value EBITDA Sales	EUR 13 million EUR 1.8 million EUR 11.4 million			



Investment





	Name	Transitec SAS / DBC	The Impact		any's carbon footprint	
	Business	Design, production, assembly and quality control of small and medium quantity series of complex metal parts	problem	of metals, and produ	nes from the purchase scrap materials (15%) let transportation to	
-		for demanding industries-automotive, aerospace, medical, and hydraulic industry	SDG	clients (4%).		
	Theme	Machining & bar cutting				
	Location	Scionzier	Impact Goals	KPI 1	Reduce carbon emissions by 25%	
	Inception	1991				
	Exit perspective	N/A				
	Date of investment	September 2021				
	Туре	OBO, minority stake, primary	% Impact Achieved			
	Amount invested	EUR 4.5 million	Achieved			
	Commitment	EUR 4.5 million				
	% ownership	44.4%				
	I					
	Enterprise Value	EUR 11.6 million				
	EBITDA	EUR 4.4 million				
	Sales	EUR 18.7 million				



Investment





<u> </u>	Name Business	RECIF Designs, manufactures, distributes and maintains robotic handling equipment for highly sensitive environments dedicated to these miconductor industry	The Impact problem SDG	dependen usage by	otprint is largely It on the machines' its clients (Scope3 am, 61.5% of carbon
	Theme Location Inception Exit perspective	Semiconductor France 1982 N/A	Impact Goals	KPI 1	Reduce carbon emissions by 25%
	Date of investment Type Amount invested Commitment % ownership	September 2021 Buy-Out, majority stake, secondary EUR 8.6 million EUR 8.6 million F	% Impact Achieved		
	Enterprise Value EBITDA Sales	EUR 15 million EUR 2.8 million EUR 10.7 million			



Investment

Financial



SDG Mapping

	UN SDG	IMPACT THEME	KPI	Quantitiative target	Company	KPI Value
	SDG 1: NO POVERTY	Financial inclusion	Number of farmers sourced from in the last 12 months	-	Wakuli	48
/ **# *#*#		Access to basic goods and services	Number of schools reached by awareness campaigns	2096	Dans Ma Culotte	0
		Sustainable agriculture	Technology Readiness Level (TRL) # achieved	-	Arborea	-
2 ZERO HUNGER		Sustainable agriculture	Environmental footprint in CO2 equivalent emissions/kg		Arborea	
	SDG 2: ZERO HUNGER	Sustainable agriculture	Number of high tech customers		30MHz	-
		Sustainable agriculture	Number of mid/low tech customers		30MHz	-
		Fitness and wellbeing	Number of blue collar equipped with protective vest	230,000	Percko	6,700
		Reproductive health	Years of hygienic protection available to poor women through foundations / universities	99,000	Dans Ma Culotte	3,766
		Ageing	Number of people over 50+ with identified dementia risk trained (prevention)	7,368	Neuronation	0
		Ageing	Number of patients in a healthcare process (treatment)	45,300	Neuronation	8,600
	6.07 ·	Biotechnology	Inclusions of data in investigational new drug application	20	Lumicks	0
		Biotechnology	Number of scientific publication	561	Lumicks	58
3 GOOD HEALTH AND WELL BEING		Biotechnology	Reduction in surgical site infections/per year	13,000	Caresyntax	1,500
	SDG 3: GOOD HEALTH	Access to healthcare	Time saved/day/op. room	16	Caresyntax	5
-w	AND WELL-BEING	Access to healthcare	Reduction in or consumables utilization and cost	73	Caresyntax	25
		Access to healthcare	Number of reductions in surgical complications	TBD	Incision	0
		Access to healthcare	Cumulative number of patients accompanied in their treatment in oncology	47,030	Wefight	0
		Access to healthcare	Cumulative number of patients referred to a doctor specialist	8,820	Wefight	0
		Access to healthcare	Number of physicians registered on the platform in Medical Deserts	29,000	360 Medical	0
		Access to healthcare	Number of in-app openings, intended for medical specialists, by general practitioners	398,000	360Medical	0
		Access to healthcare	Cumulative number of appointments made by patients based in deserts medical	537,280	Top Doctors Holding	0
		Access to healthcare	Cumulative number of appointments performed by patients without private insurance	829,946	Top Doctors Holding	0
		Access to healthcare	Time saved/month/active user	3	PSIH	2
	SDG 4: QUALITY	Access to education	Number of books sold adapted to reading disabilities	120,632	Mi Cuento	501
	EDUCATION	Access to education	Number of new titles in adapted format	140	Mi Cuento	6
		Access to education	Relevant language learning users		Lingvist	-




SDG Mapping

	UN SDG	IMPACT THEME	KPI	Quantitiative target	Company	KPI Value
	SDG 7 : AFFORDABLE AND CLEAN ENERGY	Energyefficiency	Kiloton CO2 emissions avoided	-	Taylor	-
8 BECENT WORKAND ECONOMIC GROWTH		Developed world jobs	Cumulative number of completed skill profiles	-	Skillab	276
	SDG 8: DECENT WORK AND ECONOMIC	Developed world jobs	Number of nurses equipped with protective clothing	33,000	Percko	335
íí	GROWTH	Developed world jobs Developed world jobs	Number of respondents being apprentices or blue collar Number of companies certified IMPACTINDEX	125,000 400	Choose My Company Choose My Company	13,000 0
11 SUSTAINABLE CITIES	SDG 11: SUSTAINABLE	Smart cities and mobility	Number of public facilities being accessible	3,500	Okeenea	0
≜ ∎₫⊞	COMMUNITIES	Smart cities and mobility	Number of audio-signal devices implemented in traffic lights	99,000	Okeenea	0
		Environmental health	Metric tons produced of approved cultured beef	0	Mosa Meat	0
40 MCMANNE	SDG 12: RESPONSIBLE CONSUMPTION AND PRODUCTION	Resource efficiency	Price per kg of cultured beef produced	0	Mosa Meat	0
12 RESPONSIBLE CONSUMPTION AND PRODUCTION			Cost reduction in cultured meat (in %)	TBD	Mosa Meat	0
CO		Resource efficiency	50% increase in targeted recombination events in relevant commercial specie due to the Meiogenix Technology	TBD	Meiognix	0
		Resource efficiency	3-fold increase in targeted meiotic recombination using Meiogenix Technology in any crop species in at least one cold recombination genomic location	TBD	Meiognix	0
		Resource efficiency	Recovery of a commercially relevant plant carrying a disease resistant trait devoid of the genetically linked negative agronomy using Meiogenix Technology	TBD	Meiognix	0
		Resource efficiency	Pieces of litter registrated	TBD	Litterati	0
		Resource efficiency	Number of stories of impact	0	Litterati	0
13 CLIMATE ACTION		Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	Folan	0
	SDG 13: CLIMATE	Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	AET Group	÷
	ACTION	Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	DBC	0
		Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	RECIF	0



Portfolio Breakdown







This document is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performances of a given financial instrument or index or an investment service or strategy, or simulations of past performances, or forecasts of future performances are not reliable indicators of future performances and are not guaranteed.

Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change.

Candriam consistently recommends investors to consult via our website www.candriam.com the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value ("NAV") of the funds. This information is available either in English or in local languages for each country where the fund's marketing is approved.



www.candriam.com



CLIENT RELATION OFFICES AMSTERDAM DUBAI FRANKFURT GENEVA ZURICH MADRID MILAN NEW YORK MANAGEMENT CENTERS LUXEMBOURG BRUSSELS PARIS LONDON